We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
Read MoreHide Full Article
Shares of Mustang Bio (MBIO - Free Report) were up 9.2% on Jun 12 after management announced updated results from a cohort of an ongoing single-institution phase I/II study evaluating its lead clinical candidate MB-106 in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer.
Data from the study showed that treatment with MB-106 exhibited a favorable safety and efficacy profile in WM patients, all (n=6) of whom were previously treated with Bruton's tyrosine kinase (“BTK”) inhibitors and their disease continued to progress while on BTK inhibitors.
Per management, participants treated with MB-106 achieved an overall response rate (“ORR”) of 83%, including two complete responses (“CR”). One of the patients who achieved CR remains in remission at 22 months. Also, none of the patients started treatment with an additional anti-WM treatment following MB-106 administration.
Mustang Bio’s stock has risen 20.7% in the past year against the industry‘s 7.8% decline.
Image Source: Zacks Investment Research
A CD20-targeted autologous CAR T cell therapy, MB-106, is being developed in the above-mentioned phase I/II study to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”). This study is being sponsored by Fred Hutchinson Cancer Center (“Fred Hutch”), Mustang’s research collaborator. MB-106 was licensed by Fred Hutch to Mustang in 2017.
Currently, there are no FDA-approved CAR T treatments in WM indication. Mustang believes that MB-106 has the potential to address a significant unmet need. The FDA has granted orphan drug designation to MB-106 in WM indication based on data from a company-sponsored phase I/II multicenter study evaluating MB-106 in patients with relapsed or refractory B-Cell NHL or CLL.
A popular drug approved in WM indication is Imbruvica, which is jointly marketed by pharma giants J&J (JNJ - Free Report) and AbbVie (ABBV - Free Report) . The AbbVie-J&J partnered drug was the first FDA-approved therapy in WM indication. A BTK inhibitor, AbbVie/J&J’s Imbruvica is also approved by the FDA in CLL and small lymphocytic lymphoma (“SLL”) indications.
ABBV and J&J co-exclusively market Imbruvica in the United States. However, J&J has an exclusive license to market the drug outside the United States and shares profits from the drug’s ex-U.S. sales with AbbVie.
Another better-ranked stock in the overall healthcare sector is Novartis (NVS - Free Report) , which carries the same rank as that of MBIO.
In the past 60 days, estimates for Novartis’ 2023 and 2024 earnings per share have increased from $6.57 to $6.72 and $7.08 to $7.26, respectively. Shares of Novartis are up 10.2% in the year-to-date period.
Earnings of Novartis beat estimates in each of the last four quarters, witnessing an average earnings surprise of 5.15%. In the last reported quarter, Novartis’ earnings beat estimates by 10.32%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
Shares of Mustang Bio (MBIO - Free Report) were up 9.2% on Jun 12 after management announced updated results from a cohort of an ongoing single-institution phase I/II study evaluating its lead clinical candidate MB-106 in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer.
Data from the study showed that treatment with MB-106 exhibited a favorable safety and efficacy profile in WM patients, all (n=6) of whom were previously treated with Bruton's tyrosine kinase (“BTK”) inhibitors and their disease continued to progress while on BTK inhibitors.
Per management, participants treated with MB-106 achieved an overall response rate (“ORR”) of 83%, including two complete responses (“CR”). One of the patients who achieved CR remains in remission at 22 months. Also, none of the patients started treatment with an additional anti-WM treatment following MB-106 administration.
Mustang Bio’s stock has risen 20.7% in the past year against the industry‘s 7.8% decline.
Image Source: Zacks Investment Research
A CD20-targeted autologous CAR T cell therapy, MB-106, is being developed in the above-mentioned phase I/II study to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”). This study is being sponsored by Fred Hutchinson Cancer Center (“Fred Hutch”), Mustang’s research collaborator. MB-106 was licensed by Fred Hutch to Mustang in 2017.
Currently, there are no FDA-approved CAR T treatments in WM indication. Mustang believes that MB-106 has the potential to address a significant unmet need. The FDA has granted orphan drug designation to MB-106 in WM indication based on data from a company-sponsored phase I/II multicenter study evaluating MB-106 in patients with relapsed or refractory B-Cell NHL or CLL.
A popular drug approved in WM indication is Imbruvica, which is jointly marketed by pharma giants J&J (JNJ - Free Report) and AbbVie (ABBV - Free Report) . The AbbVie-J&J partnered drug was the first FDA-approved therapy in WM indication. A BTK inhibitor, AbbVie/J&J’s Imbruvica is also approved by the FDA in CLL and small lymphocytic lymphoma (“SLL”) indications.
ABBV and J&J co-exclusively market Imbruvica in the United States. However, J&J has an exclusive license to market the drug outside the United States and shares profits from the drug’s ex-U.S. sales with AbbVie.
Mustang Bio, Inc. Price
Mustang Bio, Inc. price | Mustang Bio, Inc. Quote
Zacks Rank & Stocks to Consider
Mustang Bio currently carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Another better-ranked stock in the overall healthcare sector is Novartis (NVS - Free Report) , which carries the same rank as that of MBIO.
In the past 60 days, estimates for Novartis’ 2023 and 2024 earnings per share have increased from $6.57 to $6.72 and $7.08 to $7.26, respectively. Shares of Novartis are up 10.2% in the year-to-date period.
Earnings of Novartis beat estimates in each of the last four quarters, witnessing an average earnings surprise of 5.15%. In the last reported quarter, Novartis’ earnings beat estimates by 10.32%.